ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
알부민 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년 연간 평균 성장률(CAGR)은 9.1%로 101억 6,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 간질환의 유병률 증가, 재생의료 응용의 확대, 노년 인구 증가, 진단기술의 진화, 외래의료에 대한 의료 인프라의 전환, 최적의 단백질 수준을 유지하는 중요성에 대한 의식 증가에 기인하는 것으로 예상됩니다. 예측 기간의 주요 동향으로는 치료 용도 확대, 약물 전달 시스템에서의 채용 증가, 세포 배양 배지에서 수요 증가, 맞춤형 의료의 성장, 유전자 재조합 기술의 진보, 저알부민혈증 치료에 대한 의식의 높아짐, 혁신적인 알부민 기반 제품에 대한 연구 개발에 많은 투자가 포함됩니다.
당뇨병의 유병률 증가는 알부민 시장의 미래 성장을 견인할 것으로 보입니다. 당뇨병은 고혈당 상태가 오래 지속되는 것을 특징으로 하는 대사성 질환으로 영양 불량, 앉기 쉬운 라이프 스타일, 호르몬 상태, 비만 등의 요인에 의해 증가 경향이 있습니다. 알부민은 중요한 바이오마커로서 당뇨병 관리에 중요한 역할을 하며, 인슐린 치료 지침, 혈당 조절 모니터링, 진단 보조, 당뇨병성 케토아시도시스(DKA)와 같은 합병증을 예측하는 데 도움이 됩니다. 알부민 수치를 정상적으로 유지하는 것은 당뇨병을 효과적으로 관리하는 데 매우 중요합니다. 미국 국립의학 도서관에 따르면, 2021년 세계 당뇨병 유병률은 10.5%로 추정되며, 20-79세의 약 5억 3,660만 명이 이환하고 있습니다. 예측에 따르면 이 수치는 2045년 12.2%에 달하며 약 7억 8,320만 명이 영향을 받을 수 있습니다. 따라서 당뇨병 이환율의 상승은 알부민 시장의 성장을 가속할 것으로 예상됩니다.
알부민 시장의 주요 기업은 기술 혁신에 주력하고 있으며, 고급 기능을 갖춘 수요 증가에 대응하기 위해 동물 유래 및 인간 유래의 재조합 알부민 등의 제품을 개발하고 있습니다. 비포유류 발현계를 이용하여 생산되며, 동물 유래 성분이나 인간 유래 성분을 포함하지 않습니다. 2023년 3월에 영국의 재조합 인간 알부민(rHA) 제조업체인 Albumedix는 일본의 임상 단계 바이오테크 기업인 Heartseed Inc.와 협력하여 Heartseed의 임상 시험 중인 세포 치료제인 HS-001의 필수 부형제로서 Recombin을 도입했습니다. 다양한 질병에 대한 혁신적인 치료 접근이 기대되는 HS-001을 추진하는데 있어 중요한 이정표가 됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 그리고 경기 회복이 시장에 미치는 영향을 포함한 거시 경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 알부민 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계 알부민 시장 : 성장률 분석
세계 알부민 시장 실적 : 규모와 성장, 2019-2024
세계 알부민 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 알부민 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 알부민 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
인간 혈청 알부민
소 혈청 알부민
재조합 알부민
세계의 알부민 시장 : 용도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
치료제
의약품의 처방과 백신
미디어의 구성요소
기타 용도
세계의 알부민 시장 : 판매 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
기업 대 소비자(B2C)
기업간 거래(B2B)
세계의 알부민 시장 : 최종 사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원 및 진료소
제약 및 생명 공학 기업
연구기관
세계의 알부민 시장 : 인간 혈청 알부민유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
혈장 유래 인간 혈청 알부민
재조합 인간 혈청 알부민
인간 혈청 알부민 치료용(간질환, 화상)
인간 혈청 알부민 약물 전달 및 조사 용도
세계의 알부민 시장 : 소혈청 알부민유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
소혈청 알부민 실험실용(세포 배양용)
소 혈청 알부민 진단 키트용
백신 및 바이오의약품의 안정제로서의 소혈청 알부민
세계의 알부민 시장 : 재조합 알부민유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
재조합 인간 알부민 치료 용도
바이오의약품 제제용 재조합 알부민
화장품 및 퍼스널케어 용도의 재조합 알부민
조사 및 진단 용도를 위한 재조합 알부민
제7장 지역별, 국가별 분석
세계의 알부민 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 알부민 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
알부민 시장 : 경쟁 구도
알부민 시장 : 기업 프로파일
Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업 및 혁신 기업
CSL Limited
Grifols SA
Mitsubishi Tanabe Pharma Corporation
Octapharma AG
Kedrion SpA
Biotest AG
Jiangxi Boya Bio-Pharmaceutical Co. Ltd.
BPL(Bio Products Laboratory)
Kamada Ltd.
Proliant Biologicals
SeraCare Life Sciences Inc.
HiMedia Laboratories
Albumedix Ltd.
Medxbio Pte Ltd.
Ventria Bioscience Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
알부민 시장(2029년) : 새로운 기회를 제공하는 국가
알부민 시장(2029년) : 새로운 기회를 제공하는 부문
알부민 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Albumin is a type of protein present in blood plasma, serum, muscle, egg whites, milk, and other animal substances, as well as in various plant tissues and fluids. It is a simple protein that is heat-coagulable and water-soluble, playing a vital role in maintaining fluid balance and transporting hormones, vitamins, and enzymes throughout the body.
The primary types of albumin are human serum albumin, bovine serum albumin, and recombinant serum albumin. Human serum albumin, found in blood plasma, helps maintain osmotic pressure and transports various substances such as hormones and fatty acids. Its applications include therapeutics, drug formulation, vaccines, and media components, distributed through channels such as business-to-customer (B2C) and business-to-business (B2B). The end users of albumin include hospitals and clinics, pharmaceutical and biotechnology companies, and research institutes.
The albumin research report is one of a series of new reports from The Business Research Company that provides albumin market statistics, including the albumin industry's global market size, regional shares, competitors with an albumin market share, detailed albumin market segments, market trends and opportunities, and any further data you may need to thrive in the albumin industry. This albumin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The albumin market size has grown strongly in recent years. It will grow from $6.57 billion in 2024 to $7.18 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to advancements in biotechnology, increased demand for plasma-derived therapies, expanding applications in pharmaceuticals, high prevalence of liver diseases, regulatory approvals for albumin-based products, and globalization of healthcare leading to wider market access.
The albumin market size is expected to see strong growth in the next few years. It will grow to $10.16 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to the increasing prevalence of liver diseases, expanding applications in regenerative medicine, rising geriatric population, evolving diagnostic techniques, shifting healthcare infrastructure towards outpatient care, and growing awareness about the importance of maintaining optimal protein levels. Major trends in the forecast period include expanding therapeutic applications, rising adoption in drug delivery systems, increasing demand in cell culture media, growth in personalized medicine, advancements in recombinant technology, heightened awareness of hypoalbuminemia treatment, and significant investment in research and development for innovative albumin-based products.
The increasing prevalence of diabetes is poised to drive growth in the albumin market moving forward. Diabetes, a metabolic disorder characterized by prolonged high blood sugar levels, is on the rise due to factors such as poor nutrition, sedentary lifestyles, hormonal conditions, and obesity. Albumin plays a critical role in diabetes management as a significant biomarker, guiding insulin therapy, monitoring glycemic control, aiding diagnosis, and predicting complications such as diabetic ketoacidosis (DKA). Maintaining normal albumin levels is crucial for effectively managing diabetes. According to the National Library of Medicine, global diabetes prevalence was estimated at 10.5% in 2021, affecting approximately 536.6 million individuals aged 20-79 years. Projections suggest this figure could reach 12.2% by 2045, impacting about 783.2 million people. Therefore, the rising incidence of diabetes is expected to drive growth in the albumin market.
Leading companies in the albumin market are focusing on innovation, developing products such as animal- and human-origin-free recombinant albumin to meet increasing demand with advanced features. This type of albumin is produced using non-mammalian expression systems such as yeast and does not contain any animal- or human-derived components. For example, in March 2023, Albumedix, a UK-based manufacturer of recombinant human albumin (rHA), collaborated with Heartseed Inc., a Japan-based clinical-stage biotech company, to introduce Recombin as a critical excipient for Heartseed's investigational cell therapy, HS-001, during its first-in-human clinical trial. This partnership represents a significant milestone in advancing HS-001, promising innovative treatment approaches for various diseases. The use of recombinant technology ensures optimal performance and stability of the cell therapy, enhancing its potential for therapeutic success.
In September 2022, Sartorius AG, a Germany-based supplier of pharmaceutical and laboratory equipment, acquired Albumedix, strengthening its position in the expanding sector of advanced therapies and vaccines. This acquisition aligns Albumedix's innovative recombinant albumin technology with Sartorius' portfolio of cell culture media and process solutions, bolstering the company's offerings in the dynamic market landscape of advanced therapies. Albumedix Ltd. is a UK-based provider of high-quality recombinant human albumin solutions.
Major companies operating in the albumin market are Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, Baxter International Inc., CSL Limited, Grifols SA, Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Kedrion S.p.A., Biotest AG, Jiangxi Boya Bio-Pharmaceutical Co. Ltd., BPL (Bio Products Laboratory), Kamada Ltd., Proliant Biologicals, SeraCare Life Sciences Inc., HiMedia Laboratories, Albumedix Ltd., Medxbio Pte Ltd., Ventria Bioscience Inc., China Biologic Products Holdings Inc.
North America was the largest region in the albumin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the albumin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The albumin market consists of sales of egg albumin, plant-based albumin, and recombinant human albumin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Albumin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on albumin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for albumin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The albumin market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Human Serum Albumin; Bovine Serum Albumin; Recombinant Albumin
2) By Application: Therapeutics; Drug Formulation And Vaccines; Component Of Media; Other Applications
3) By Sales Channel: Business-To-Consumer (B2C); Business-To-Business (B2B)
4) By End-User: Hospitals And Clinics; Pharmaceutical And Biotechnology Companies; Research Institutes
Subsegments:
1) By Human Serum Albumin: Plasma-Derived Human Serum Albumin; Recombinant Human Serum Albumin; Human Serum Albumin For Therapeutic Use (In Liver Disease, Burns); Human Serum Albumin For Drug Delivery And Research Applications
2) By Bovine Serum Albumin: Bovine Serum Albumin For Laboratory Use (In Cell Culture); Bovine Serum Albumin For Diagnostic Kits; Bovine Serum Albumin As A Stabilizer In Vaccines And Biopharmaceuticals
3) By Recombinant Albumin: Recombinant Human Albumin For Therapeutic Applications; Recombinant Albumin For Biopharmaceutical Formulation; Recombinant Albumin For Cosmetic And Personal Care Applications; Recombinant Albumin For Research And Diagnostic Applications
Companies Mentioned: Bristol-Myers Squibb Company; Thermo Fisher Scientific Inc.; Takeda Pharmaceutical Company Limited; Merck KGaA; Baxter International Inc.
